Clinical Trial: Study of SKB103 in HER2-negative Breast Cancer

U.S., Aug. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07774624) titled 'Study of SKB103 in HER2-negative Breast Cancer' on Aug. 12.

Brief Summary: This is a Phase I/II clinical study to evaluate the safety and efficacy of SKB103 in participants with advanced (locally advanced, recurrent, or metastatic) HER2-negative breast cancer. The study includes a Phase 1 dose escalation stage and a Phase 2 indication expansion stage.

Study Start Date: Aug. 31

Study Type: INTERVENTIONAL

Condition: Breast Cancer

Intervention: DRUG: SKB103 monotherapy

SKB103 for injection, administered as monotherapy via intravenous (IV) infusion on Day 1 of each 21-day cycle (every 3 weeks, Q3W). Treatment continues until radi...